Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05844384 · ClinicalTrials.gov registry record · NA

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

A NA study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by 59th Medical Wing.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05844384 is a NA study of Ocular Hypertension and Primary Open Angle Glaucoma that is actively recruiting participants, run by 59th Medical Wing. The registered enrollment target is 30 participants, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05844384, a NA study of Ocular Hypertension and Primary Open Angle Glaucoma, is actively recruiting participants, sponsored by 59th Medical Wing.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.

Interventions

  • DEVICE Nanodropper
  • DEVICE Regular dropper

Study Locations (1)

Texas

  • Wilford Hall Ambulatory Surgical Center - Lackland Air Force Base

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-03-17
Est. Completion 2024-03-17
Phase NA

Sponsor

59th Medical Wing

20 total trials

What the Registry Record Tells You About NCT05844384

The ClinicalTrials.gov registry entry for NCT05844384 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is 59th Medical Wing, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Nanodropper is the first listed.

NCT05844384 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05844384 about?

NCT05844384 is a clinical study titled "Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial". This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall A...

What is the current status of trial NCT05844384?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-03-17. Estimated completion is 2024-03-17.

What conditions does trial NCT05844384 study?

This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma.

What interventions are being tested in trial NCT05844384?

The interventions under investigation include: Nanodropper (DEVICE), Regular dropper (DEVICE).

Who is sponsoring clinical trial NCT05844384?

This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05844384 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ocular Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.